Reply by Authors

J Urol. 2021 Apr;205(4):1108-1109. doi: 10.1097/JU.0000000000001437.02. Epub 2021 Jan 25.

Dennie Meijer^{1

2}, Henk B Luiting³, Pim J van Leeuwen⁴, Sebastiaan Remmers³, Bernard H E Jansen^{1

2}, Yves J L Bodar^{1

2}, Thelma Witteveen⁵, Eva E Schaake⁵, Henk G van der Poel⁴, Maurits Wondergem⁶, Martijn B Busstra³, Jakko A Nieuwenhuijzen^{1

4}, Philip Meijnen⁷, Tessa Brabander⁸, R Jeroen A van Moorselaar¹, N Harry Hendrikse^{2

9}, Daniela E Oprea-Lager², Monique J Roobol³, André N Vis^{1

4}

¹ Amsterdam University Medical Center, VU University, Department of Urology, Prostate Cancer Network Amsterdam, Amsterdam, The Netherlands.
² Amsterdam University Medical Center, VU University, Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.
³ Erasmus University Medical Center, Department of Urology, Rotterdam, The Netherlands.
⁴ The Netherlands Cancer Institute, Department of Urology, Prostate Cancer Network Amsterdam, Amsterdam, The Netherlands.
⁵ The Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam, The Netherlands.
⁶ Noordwest Ziekenhuisgroep, Department of Nuclear Medicine, Alkmaar, The Netherlands.
⁷ Amsterdam University Medical Center, VU University, Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
⁸ Erasmus University Medical Center, Department of Radiology & Nuclear Medicine, Rotterdam, The Netherlands.
⁹ Amsterdam University Medical Center, VU University, Department of Clinical Pharmacology and Pharmacy, Amsterdam, The Netherlands.

No abstract available

Publication types